HYLATOPICPLUS LOTION Rx
Generic Name and Formulations:
Water, glycerin, ethylhexyl palmitate, propylene glycol, cetearyl alcohol, theobroma grandiflorum seed butter, dicetyl phosphate, dimethicone, petrolatum, tocopheryl acetate, steareth-10, phenoxyethanol, ceteareth-10 phosphate, hydroxypropyl bispalmitamide MEA (ceramide), disodium EDTA, sodium hyaluronate and sodium hydroxide; lotion.
Encore Dermatology, Inc.
Indications for HYLATOPICPLUS LOTION:
Dermatitis (including radiation dermatitis). Dry skin.
Adults and Children:
Apply and massage into affected area 3 times daily or as needed. Broken skin: may be occluded.
Avoid eyes and exposure to sun. Treatment may be continued during antiinfective therapy. Reevaluate if no improvement after 10–14 days.
Radiation therapy: may dissolve fuchsin dye; do not use 4 hours prior to session.
Foam—100g, 150g; Crm—100g, 450g, Lotion—14oz
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Ketogenic Diet as an Adjunct to Cancer Treatment
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Blinatumomab-Ponatinib Salvage Therapy in B-Cell Acute Lymphoblastic Leukemia: Case Report of Benefit
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer